RMD Open · 2017 · 106 citations · 19 references
MedicineClinical SciencesInternal MedicineAutoimmunityInflammationRheumatologyAutoimmune BiomarkersAutoimmune DiseasesAutoimmune Rheumatic DiseasesInflammatory ArthritisInflammatory BiomarkersRheumatoid ArthritisClinical Validation StudiesDisease Activity MeasurementEarly Rheumatoid ArthritisRheumatoid Arthritis DiagnosticsRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
BACKGROUND: In most patients with rheumatoid arthritis (RA), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) is lower than DAS28 erythrocyte sedimentation rate (DAS28-ESR), suggesting that use of the DAS28-ESR cut-off to assess high disease activity (HDA) with DAS28-CRP may underestimate the number of patients with HDA. We determined the DAS28-CRP value corresponding to the validated DAS28-ESR cut-off for HDA. METHODS: Baseline data were pooled from 2 clinical studies evaluating etanercept (ETN) plus methotrexate (MTX) or MTX in early RA; DAS28-CRP and DAS28-ESR were obtained, allowing the determination of the DAS28-CRP HDA value best corresponding to the DAS28-ESR cut-off of >5.1. RESULTS: At baseline, as expected, fewer patients had HDA by DAS28-CRP than DAS28-ESR; DAS28-CRP>5.1 and DAS28-ESR>5.1 had only modest agreement (κ coefficients 0.45-0.54). Mean DAS28-CRP and DAS28-ESR were 5.7 and 6.2, respectively, in the ETN+MTX group (n=571), and 6.0 and 6.5 in the MTX group (n=262). A DAS28-CRP cut-off of 4.6 corresponded to a DAS28-ESR cut-off of 5.1. CONCLUSIONS: We have shown that a DAS28-CRP of 4.6 corresponds to 5.1 for DAS28-ESR. Since this is substantially lower than the DAS28-ESR cut-off of 5.1, using 5.1 as the cut-off for DAS28-CRP underestimates disease activity in RA. TRIAL REGISTRATION NUMBER: NCT00195494; NCT00913458.
19
Lars Klareskog, Désirée van der Heijde, J Jäger et al. · The Lancet · 2004 · 1.8K citations
Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text
Medicine, Immunology, Pharmacology +13
George A. Wells, J-C Becker, J. Teng et al. · Annals of the Rheumatic Diseases · 2008 · 892 citations · Full text
Paul Emery, Ferdinand C. Breedveld, Stephen Hall et al. · The Lancet · 2008 · 817 citations